ClinicalTrials.gg
Not yet recruitingNCT07846826MIT-MDO-PTUpdated Sep 29, 2026

Metacognitive Interpersonal Therapy for Male Intimate Partner Violence Perpetrators With Personality Disorders

An interventional study of Metacognitive Interpersonal Therapy for Male Domestic Offenders, Portuguese adaptation (MIT-MDO-PT) in Intimate Partner Violence and Personality Disorders, sponsored by Hugo César Vicente. Not yet recruiting at 1 site in Portugal. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Hugo César Vicente · Not applicable, Interventional, and Treatment

How we know

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Study summary

This study evaluates the preliminary efficacy of MIT-MDO-PT, the European Portuguese cultural and linguistic adaptation of Metacognitive Interpersonal Therapy for Male Domestic Offenders (MIT-MDO), in adult men under judicial supervision for intimate partner violence (IPV) offences who meet criteria for a personality disorder. MIT-MDO-PT is an individual psychotherapy of 24 weekly 50-minute sessions delivered over approximately six months in four phases (case formulation and metacognitive assessment; mentalization and affect regulation; memory rescripting and shame transformation; consolidation and relapse prevention). The study uses a preregistered nonconcurrent multiple-baseline single-case experimental design across participants (target N = 5-7; enrolment ceiling 7): each participant completes a baseline phase with weekly monitoring (target of five data points), and treatment onsets are fixed a priori and staggered by at least three weeks between participants to provide internal experimental control without randomization. Primary outcomes are self-reported IPV perpetration (Revised Conflict Tactics Scales, CTS2), metacognition (Metacognition Self-Assessment Scale, MSAS) and personality pathology (Personality Inventory for DSM-5, PID-5), assessed at baseline (T0), after sessions 8 (T1), 16 (T2) and 24 (T3) and at 8-10-week follow-up (T4), with weekly monitoring of IPV (CTS2 physical assault and psychological aggression subscales) and psychological distress (CORE-10) throughout baseline and treatment. Where available, partners are assessed independently by a hospital victim-support service at T0 and T3 (Danger Assessment-5, CTS2 partner version, Psychological Maltreatment of Women Inventory-Short Form). Outcome assessment at T0, T3 and T4 is performed by an assessor independent of the therapist. Objectively recorded violence-related incidents (police or judicial occurrences, breaches notified by the supervising services, hospital safety-protocol activations) are collected as a secondary outcome. Analyses are conducted per participant (reliable change index, percentage of non-overlapping data, non-overlap of all pairs, Tau-U, structured visual analysis), with study-level conclusions based on replication across participants. Treatment fidelity is monitored through structured session notes and blind rating of 20% of sessions. The study is preregistered on the Open Science Framework (osf.io/wqpnc; protocol update v3.1, September 2026) and has a favourable opinion from the Ethics Committee of the University of Beira Interior, subject to the formal authorizations of the referring institutions.

Read the detailed description

Background. Court-mandated psychoeducational programmes for intimate partner violence (IPV) perpetrators show small or null effects on recidivism and high attrition, particularly among men with personality pathology. Metacognitive Interpersonal Therapy (MIT) targets the metacognitive dysfunctions (monitoring, differentiation, integration, decentration, mastery) and maladaptive interpersonal schemas that underlie personality disorders. Its adaptation to male domestic offenders (MIT-MDO) has shown promising results in a proof-of-concept case series (Pasetto et al., 2026). The European Portuguese adaptation (MIT-MDO-PT) was developed following established cross-cultural adaptation standards and is preregistered separately (osf.io/r2x8g). The study protocol is registered on the Open Science Framework (osf.io/wqpnc; update v3.1, September 2026).

Design. Nonconcurrent multiple-baseline single-case experimental design across participants (single series; participants enter at different calendar times). Phase A (baseline): weekly monitoring with a target of five data points (minimum of three only when imminent risk requires earlier treatment; no data-dependent extension), using the brief monitoring set (CTS2 physical assault and psychological aggression subscales, 1-week recall, plus CORE-10). Phase B (intervention): 24 individual weekly sessions. Treatment onsets are fixed a priori, before baseline data are inspected, and staggered by at least three weeks between participants irrespective of referral pathway, so that the A-to-B change occurs at each participant's own onset rather than at a common calendar time, controlling for maturation, history and instrumentation drift. No randomization. Outcome assessment at T0, T3 (including the SCID-5-PD) and T4 is performed by the same assessor, independent of the therapist; the weekly series is self-completed on a secure platform before each session without the therapist present. Treatment fidelity is rated blindly on 20% of sessions by an independent rater (inter-rater ICC target >= .80 on 10% of rated sessions). Participants at imminent risk of harming the victim move directly to treatment, and the deviation is reported.

Assessment schedule. T0 (baseline): complete battery. T1 (after Session 8): CTS2, MSAS, CORE-OM, IRI. T2 (after Session 16): T1 set plus EDRE, IIP-32, TOSCA-3. T3 (after Session 24): complete battery and exit interview. T4 (8-10 weeks after Session 24): CTS2, MSAS, PID-5, IIP-32, CORE-OM, TOSCA-3, IRI. Weekly throughout Phases A and B: CTS2 physical assault and psychological aggression subscales and CORE-10 (act counts, 1-week recall). CTS2 at T1-T4 uses a "since the last assessment" recall period. Recorded violence-related incidents (new police or judicial occurrences, breaches of the judicial measure notified by DGRSP, activations of the hospital safety protocol) are logged per participant and phase as an objective secondary outcome; a serious adverse event is defined a priori and a study-level stopping rule applies. Screening for psychopathy: candidates meeting SCID-5-PD criteria for antisocial personality disorder complete the Self-Report Psychopathy Scale - Short Form (SRP-SF, Portuguese version); a total score of 70 or above is exclusionary. WAI-SR at Sessions 4, 8, 12, 16, 20 and 24.

Partner assessment. Administered exclusively by the victim-support team of Hospital Beatriz Angelo at T0 and T3, in fixed order: Danger Assessment-5 first (an elevated score immediately triggers the hospital safety protocol), then CTS2 partner version and PMWI-SF. Partner data are stored by the hospital separately from the research database; the research team receives de-identified data only. Two to five complete dyads are expected.

Analysis. No group-level inferential models. Per participant: reliable change index (Jacobson \& Truax) with \|RCI\| >= 1.96; percentage of non-overlapping data (PND >= 70%) and non-overlap of all pairs (NAP >= 0.66) on the weekly series, with Tau-U (uncorrected as the main index; trend-corrected as sensitivity analysis) and baseline-to-treatment rate difference; structured visual analysis following a named protocol (level, trend, variability, immediacy, overlap, consistency). Partner-exposure stratum (cohabiting, regular contact, no contact) is recorded and reported for the interpretation of the weekly IPV series. Participant-level decision: RCI criterion met plus at least one corroborating criterion. Study-level support when replicated in at least 3 of 5 participants (at least 4 if N = 6-7). Temporal precedence of metacognitive change over violence reduction examined by visual analysis (exploratory). Dyad-level concordance and change in number of personality disorder diagnoses are descriptive. Missing items below 20% within a scale are imputed by person mean; 20% or more, the score is not computed; no imputation of weekly series; last observation carried forward only as sensitivity analysis. Analysis code is written before data access.

Therapist and supervision. The intervention is delivered by the principal investigator (formal MIT training, Levels I-III) under weekly clinical supervision by the developer of MIT-MDO. Fidelity: structured session notes for all sessions; blind rating of 20% of sessions with the MIT-MDO-PT Session Fidelity Checklist; adherence threshold >= 80% for inclusion in primary efficacy analyses.

Start condition. Recruitment, data collection and intervention begin, for each referral pathway, only after the formal authorization of the corresponding referring institution (Hospital Beatriz Angelo; Directorate-General for Reintegration and Prison Services) has been presented to the Ethics Committee of the University of Beira Interior, closing the condition attached to its favourable opinion; the two pathways may open on different dates. Enrolment window: January to June 2027; ceiling of 7 participants including dropouts; replacement only before Session 12 and within the window; fewer than three completers triggers a feasibility report. Participants referred by the hospital are seen at the Centre for the Rehabilitation of Domestic Violence Perpetrators (CRAVDA) of Loures Municipality; the site for participants referred by the prison and reintegration services will be specified before that pathway opens.

Data sharing. De-identified participant-level data and analysis code will be deposited on the Open Science Framework at study end, subject to ethical and legal constraints; partner-reported data only in aggregate form.

02

Conditions studied

  • Intimate Partner Violence
  • Personality Disorders

Browse trials for

Keywords

  • metacognition
  • Metacognitive Interpersonal Therapy
  • domestic violence perpetrators
  • single-case experimental design
  • multiple baseline
  • forensic psychotherapy
  • Portugal
03

In context

Personality Disorders

127 studies on the registry are indexed under Personality Disorders; 25 are open to participants now.

This study's planned enrollment of 7 is below the median of 82 across 82 interventional studies indexed under Personality Disorders.

Browse Personality Disorders studies →

Lead sponsor

This is the only study on the registry with Hugo César Vicente as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male, aged 18 years or older
  • Under judicial supervision (e.g., suspended sentence, provisional suspension of proceedings, or other court-ordered measure) for intimate partner violence offences, referred by the Directorate-General for Reintegration and Prison Services (DGRSP) or by the Hospital Beatriz Ângelo victim-support service
  • Personality disorder confirmed by the SCID-5-PD (at least one diagnosis) AND elevation of at least one PID-5 domain (T-score >= 60, Portuguese norms)
  • Current or recent intimate partner violence perpetration
  • Voluntary , given independently of the judicial mandate
  • Fluency in Portuguese
  • Ability to commit to the 24-session weekly protocol

Exclusion criteria

Exclusion Criteria:

  • Psychopathy, operationalised as antisocial personality disorder confirmed by the SCID-5-PD together with a total score of 70 or above on the Self-Report Psychopathy Scale - Short Form (SRP-SF, European Portuguese version), administered at screening only to candidates meeting antisocial personality disorder criteria; clinical indicators from the screening interview and the referral file (generalised instrumental violence, absence of remorse and of affective bonding) are recorded as supporting information
  • Active psychosis or severe cognitive impairment
  • Imminent risk of harm to the victim requiring immediate protective intervention
  • Substance dependence requiring concurrent intensive treatment
  • Concurrent psychotherapy (ongoing pharmacotherapy is permitted)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (estimated)

Study arms

  • Experimental
    MIT-MDO-PT

    Adult men under judicial supervision for intimate partner violence with a personality disorder receive 24 individual weekly 50-minute sessions of MIT-MDO-PT after a baseline phase with weekly monitoring (target of five weekly data points; minimum of three only under imminent risk). Treatment onsets are fixed a priori and staggered by at least three weeks between participants (nonconcurrent multiple-baseline design).

    Behavioral: Metacognitive Interpersonal Therapy for Male Domestic Offenders, Portuguese adaptation (MIT-MDO-PT)

Interventions

  • BehavioralMetacognitive Interpersonal Therapy for Male Domestic Offenders, Portuguese adaptation (MIT-MDO-PT)

    Manualised individual psychotherapy (24 weekly sessions, 50 minutes, approximately 6 months) adapted to European Portuguese from MIT-MDO. Phase I (Sessions 1-8): shared case formulation and metacognitive assessment; Phase II (Sessions 9-16): mentalization and affect regulation; Phase III (Sessions 17-21): memory rescripting and shame transformation; Phase IV (Sessions 22-24): consolidation and relapse prevention. Delivered by a psychologist trained in MIT (Levels I-III) under weekly clinical supervision by the model developer. Fidelity: structured session notes (100% of sessions) and blind rating of 20% of sessions with the MIT-MDO-PT Session Fidelity Checklist; adherence threshold \>= 80%.

    Also known as: MIT-MDO, Terapia Metacognitiva Interpessoal para Agressores de Violência Doméstica

06

What researchers measure

Primary outcomes

  1. Change in self-reported intimate partner violence perpetration (CTS2)

    Revised Conflict Tactics Scales (CTS2), perpetration scales (physical assault, psychological aggression, sexual coercion, injury); European Portuguese version. Metric: reliable change index (RCI, Jacobson \& Truax) between T0 and T3; \|RCI\| \>= 1.96 indicates reliable change; decrease = improvement.

    Time frame: Baseline (T0) and end of treatment (T3, after Session 24, approximately 6 months after treatment onset)

  2. Change in metacognition (MSAS)

    Metacognition Self-Assessment Scale (MSAS; Pedone et al., 2017; European Portuguese version: Faustino et al., 2021; 18 items; total score and four factor scores: self-reflexivity, critical distance, mastery, understanding other minds). Metric: RCI between T0 and T3 on the total score (\|RCI\| \>= 1.96; increase = improvement). Factor scores reported descriptively.

    Time frame: Baseline (T0) and end of treatment (T3, after Session 24, approximately 6 months after treatment onset)

  3. Change in personality pathology (PID-5)

    Personality Inventory for DSM-5 (PID-5), adult form, five domain scores (T-scores, Portuguese norms). Metric: RCI between T0 and T3 per domain (\|RCI\| \>= 1.96; decrease = improvement). Facets reported descriptively.

    Time frame: Baseline (T0) and end of treatment (T3, after Session 24, approximately 6 months after treatment onset)

Secondary outcomes

  1. Weekly intimate partner violence monitoring series (CTS2 subscales)

    Sum of CTS2 physical assault and psychological aggression subscales (act counts, 1-week recall), self-completed by the participant on a secure platform before each session, collected weekly throughout baseline (Phase A) and treatment (Phase B). Metrics: percentage of non-overlapping data (PND \>= 70%) and non-overlap of all pairs (NAP \>= 0.66) between Phase A and Phase B, Tau-U (uncorrected as main index; trend-corrected as sensitivity analysis) with 95% CI, baseline-to-treatment rate difference, plus structured visual analysis following a named protocol (level, trend, variability, immediacy, overlap, consistency). Reported by partner-exposure stratum (cohabiting, regular contact, no contact).

    Time frame: Weekly from start of baseline (target of five weekly points) through Session 24 (approximately 7-8 months per participant)

  2. Weekly psychological distress (CORE-10)

    CORE-10 total score collected weekly throughout Phases A and B. Metrics: PND, NAP and structured visual analysis, Phase A versus Phase B.

    Time frame: Weekly from start of baseline (3-5 weeks) through Session 24 (approximately 7-8 months per participant)

  3. Maintenance of gains at follow-up (CTS2, MSAS, PID-5)

    RCI between T0 and T4 on the CTS2, MSAS total score and PID-5 domains; maintenance supported when \|RCI\| \>= 1.96 with no reliable deterioration between T3 and T4.

    Time frame: Baseline (T0) and follow-up (T4, 8-10 weeks after Session 24)

  4. Change in global psychological distress (CORE-OM)

    Clinical Outcomes in Routine Evaluation - Outcome Measure (CORE-OM), total score, Portuguese version. Metric: RCI T0-T3 (\|RCI\| \>= 1.96; decrease = improvement).

    Time frame: Baseline (T0), 8 weeks (T1), 16 weeks (T2), 24 weeks (T3, end of treatment) and 32-34 weeks (T4, follow-up) after treatment onset

  5. Change in interpersonal problems (IIP-32)

    Inventory of Interpersonal Problems - 32 items (IIP-32), total score. Metric: RCI T0-T3 (\|RCI\| \>= 1.96; decrease = improvement).

    Time frame: Baseline (T0), 16 weeks (T2), 24 weeks (T3, end of treatment) and 32-34 weeks (T4, follow-up) after treatment onset

  6. Change in emotion dysregulation (EDRE/DERS)

    Difficulties in Emotion Regulation Scale, Portuguese version (EDRE), total score. Metric: RCI T0-T3 (\|RCI\| \>= 1.96; decrease = improvement).

    Time frame: Baseline (T0), 16 weeks (T2) and 24 weeks (T3, end of treatment) after treatment onset

  7. Change in impulsivity (SUPPS-P)

    Short UPPS-P Impulsive Behavior Scale (SUPPS-P), total and facet scores, Portuguese version. Metric: RCI T0-T3 (\|RCI\| \>= 1.96; decrease = improvement).

    Time frame: Baseline (T0) and 24 weeks after treatment onset (T3, end of treatment)

  8. Change in alexithymia (TAS-20)

    Toronto Alexithymia Scale - 20 items (TAS-20), total score, Portuguese version. Metric: RCI T0-T3 (\|RCI\| \>= 1.96; decrease = improvement).

    Time frame: Baseline (T0) and 24 weeks after treatment onset (T3, end of treatment)

  9. Change in shame- and guilt-proneness (TOSCA-3)

    Test of Self-Conscious Affect (TOSCA-3), shame-proneness and guilt-proneness scales. Metric: RCI T0-T3 (\|RCI\| \>= 1.96).

    Time frame: Baseline (T0), 16 weeks (T2), 24 weeks (T3, end of treatment) and 32-34 weeks (T4, follow-up) after treatment onset

  10. Change in number of personality disorder diagnoses (SCID-5-PD)

    Structured Clinical Interview for DSM-5 Personality Disorders (SCID-5-PD): number of personality disorder diagnoses met. Descriptive reporting only (no inferential threshold).

    Time frame: Baseline (T0) and 24 weeks after treatment onset (T3, end of treatment)

  11. Partner-reported intimate partner violence (CTS2-P and PMWI-SF) - external validation

    CTS2 partner version (CTS2-P) and Psychological Maltreatment of Women Inventory - Short Form (PMWI-SF), administered exclusively by hospital victim-support staff. Metric: per-informant change classification and dyad-level concordance category with perpetrator report (descriptive); ICC(2,1) exploratory only if at least 5 complete dyads.

    Time frame: Baseline (T0) and 24 weeks after treatment onset (T3, end of treatment)

  12. Temporal precedence of metacognitive change over violence reduction (exploratory)

    Per-participant visual analysis of the MSAS trajectory (T0-T2) and the weekly CTS2 monitoring series, classified as temporal precedence present, absent or indeterminate. No formal mediation model (N = 5-7).

    Time frame: Baseline (T0) through 24 weeks after treatment onset (T3, end of treatment)

  13. Recorded violence-related incidents

    Objectively recorded events, independent of self-report: new police or judicial occurrences for violence, breaches of the judicial measure notified by the Directorate-General for Reintegration and Prison Services, and activations of the hospital safety protocol. Counts per participant and per phase (baseline, treatment, follow-up), reported descriptively without a formal hypothesis. Any incident meeting the a priori definition of a serious adverse event is reported to the Ethics Committee and triggers the study-level stopping rule.

    Time frame: From consent through follow-up (T4, 8-10 weeks after Session 24; approximately 11 months per participant)

Other outcomes

  1. Working alliance (WAI-SR)

    Working Alliance Inventory - Short Revised (WAI-SR), total score; descriptive process variable.

    Time frame: Weeks 4, 8, 12, 16, 20 and 24 after treatment onset (Sessions 4, 8, 12, 16, 20 and 24)

  2. Empathy (IRI)

    Interpersonal Reactivity Index (IRI), subscale scores, Portuguese version; descriptive process variable.

    Time frame: Baseline (T0), 8 weeks (T1), 16 weeks (T2), 24 weeks (T3, end of treatment) and 32-34 weeks (T4, follow-up) after treatment onset

  3. Treatment fidelity index (TFI)

    Percentage of protocol-required elements implemented per session, rated blindly by an independent rater on 20% of sessions with the MIT-MDO-PT Session Fidelity Checklist; inter-rater reliability (ICC) on 10% of rated sessions; participant mean \>= 80% required for inclusion in primary efficacy analyses.

    Time frame: Throughout treatment (24 weekly sessions, approximately 6 months)

  4. Partner danger assessment (DA-5) - safety screening

    Danger Assessment-5 (DA-5), administered first at each partner assessment by hospital victim-support staff; an elevated score triggers the hospital safety protocol. Descriptive reporting.

    Time frame: Baseline (T0) and 24 weeks after treatment onset (T3, end of treatment)

  5. Feasibility: number of treatment sessions attended (retention)

    Number of MIT-MDO-PT sessions attended by each participant, out of 24 scheduled sessions. Descriptive reporting per participant; completion defined as attendance at 20 or more sessions.

    Time frame: Through end of treatment, 24 weeks after treatment onset

  6. Feasibility: recruitment rate

    Number of participants enrolled per month during the enrolment window (January to June 2027), by referral pathway. Descriptive reporting.

    Time frame: Through end of enrolment window, up to 6 months from study start

  7. Feasibility: percentage of scheduled assessments completed

    Percentage of scheduled assessment occasions (T0 to T4 and weekly monitoring points) completed by each participant. Descriptive reporting.

    Time frame: Through follow-up, 32-34 weeks after treatment onset (T4)

  8. Feasibility: number of complete partner dyads

    Number of participants for whom the partner completed both partner assessments (T0 and T3) with the hospital victim-support service. Descriptive reporting.

    Time frame: Through end of treatment, 24 weeks after treatment onset (T3)

  9. Feasibility: number of participants who discontinued, by reason

    Number of participants who discontinued the intervention before Session 24, classified by reason for discontinuation (e.g., withdrawal of consent, breach of judicial measure, relocation, exclusion for safety). Descriptive reporting.

    Time frame: Through end of treatment, 24 weeks after treatment onset (T3)

07

Study locations

1 site
  • Centre for the Rehabilitation of Domestic Violence Perpetrators (CRAVDA), Loures Municipality
    Loures, Lisbon District, Portugal
08

References and documents

Publications

  • Misso D, Schweitzer RD, Dimaggio G. Metacognition and mentalization in intimate partner violence perpetrators: Theoretical and clinical implications. J Psychother Integr. 2019;29(4):359-375. doi:10.1037/int0000111
  • Pasetto A, Misso D, Velotti P, Dimaggio G. Metacognitive interpersonal therapy for male domestic offenders (MIT-MDO) with personality disorders: A proof-of-concept case series. Psychol Psychother. 2026 Jun;99(2):463-483. doi: 10.1111/papt.70036. Epub 2026 Jan 5. PubMed 41490723 ↗

Individual participant data

Plan to share: Yes — De-identified participant-level data (weekly repeated measures and pre/post questionnaire scores) and the analysis code will be deposited on the Open Science Framework (OSF) project page at study completion, subject to ethical and legal constraints (judicially supervised participants; approval by the UBI Ethics Committee). Partner-reported data will be shared only in aggregate or fully de-identified form to protect victim safety. Session recordings and clinical notes will not be shared.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Data and code will become available within 12 months after study completion (anticipated by December 2028) and will remain available indefinitely on OSF.

Access criteria: Open access to de-identified quantitative data and code via OSF. Any request for additional variables will be assessed by the Principal Investigator and the UBI Ethics Committee, in accordance with GDPR and Portuguese law; data-use agreements may be required.

Data sharing details ↗ · osf.io

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Mar 2028, 14 months later.

Of 39 non-industry interventional studies with no phase under Personality Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's planned 14 months is below that.

Counting every sponsor, half of 42 studies reached it within 28 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2026
First posted
Sep 29, 2026
StartEst.
Jan 2027
Primary completionEst.
Mar 2028
CompletionEst.
Jun 2028
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07846826
Lead sponsor
Hugo César Vicente
Responsible party
Hugo César Vicente (Principal Investigator, Doctoral Programme in Clinical and Health Psychology, University of Beira Interior) — Sponsor-investigator
First posted
Sep 29, 2026
Start date
Jan 2027 (estimated)
Primary completion
Mar 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

Hugo C Vicente, MSc
Contact
hugo.cesar.vicente@ubi.pt
+351 913103116
Hugo C Vicente, MSc
principal investigator · University of Beira Interior

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion